Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AEterna Zentaris Inc (NASDAQ:AEZS)

3.44
Delayed Data
As of Jul 22
 -0.07 / -1.99%
Today’s Change
2.60
Today|||52-Week Range
22.01
-23.21%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$34.2M

Company Description

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Quebec, Canada.

Contact Information

Æterna Zentaris, Inc.
1405, boulevard du Parc-Technologiqu
Québec Qubec G1P 4P5
P:(418) 652-8525
Investor Relations:
(843) 900-3211

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

David A. DoddPresident, Chief Executive Officer & Director
Geneviève LemaireChief Accounting Officer & Vice President-Finance
Richard SachseSenior VP, Chief Scientific & Medical Officer
Philip A. TheodoreSecretary, Chief Administrative Officer & SVP
Eckhard G. GuentherVice President-Business Development